Home      About us      Services      Case Study      Drug R & D      Products      Consulting      News
 
HBV Poster AASLD2016
STG-175 Paper on PLOS ONE, 2016
HCV Poster EASL2016
HCV Poster AASLD2015


Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/bbparser.php on line 137

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 506

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 517

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/bbparser.php on line 137

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 506

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 517

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/bbparser.php on line 137

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 506

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 517

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/bbparser.php on line 137

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 506

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 517
November of 2011
Gilead to Buy Pharmasset for $11 Billion
By Andrew Pollack and Michael J. de la Merced, November 21, 2011, The New York Time.
Gilead Sciences made a bold move on Monday to capture the lead in developing the next generation of hepatitis C drugs, agreeing to pay $11 billion in cash for Pharmasset.
Pharmasset, based in Princeton, N.J., is pushing to develop the first all-oral treatment regimen, doing away with the need for interferon. Its drug candidate, PSI-7977, has just entered the final phase of clinical testing and could be on the market by 2014, Gilead said. Pharmasset is "way ahead of everybody else," Norbert W. Bischofberger, Gilead's executive vice president for research and development, told analysts in a Monday morning conference call.
But Gilead's bid to dominate the market comes at a high price. It will pay $137 a share in cash, nearly 89 percent above Pharmasset's closing price on Friday. Even before the deal, shares of Pharmasset had risen more than 240 percent over the last year on expectations for PSI-7977.
Investors balked at the deal on Monday, with shares of Gilead falling 9 percent on the announcement.
"For Gilead to give up effectively one-third of their value for an unproven asset still subject to significant ongoing clinical risk seems remarkable," Geoffrey Porges, biotechnology analyst at Sanford C. Bernstein & Company, wrote in a note Monday.


October of 2010
Our additional cyclosporine analogs have been tested for their anti HCV activity compared to clinical trial phase II cyclosporine analogs. The testing was performed by a leading research institution in the USA. It proved that our analogs were more effective against HCV, especially if the testing was conducted with 40% human serum present.


February of 2010
February 9, 2010--Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive license agreement with Novartis for the development, manufacture and commercialization of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialization rights to Debio 025 except for Japan. Under the terms of the agreement, Novartis will pay Debiopharm an upfront, development and sales milestones as well as royalties. This transaction is subject to customary regulatory approvals.


March of 2009
Our anti HCV cyclosporine analogs have been tested compared to clinical trial phase II cyclosporine analogs, for their anti HCV activity. The testing was performed by a large pharmaceutical company in the USA. Test results showed that our analogs were more effective against HCV, especially if the testing was conducted with 40% human serum present.


Older news.
< 1 2 3 4 5 6 >

 
 

 

 

Copyright © 2009 - 2018  S & T Global, Inc. All rights reserved